Question 1

What did the study find?

Accepted Answer

Across the 10 studies, ACL incidence stayed low and essentially flat, under 1 ACL injury per team per season in almost every dataset, with only the 2003 to 2004 German league cohort reaching 1.2 per team per season; some of the most recent seasons recorded the lowest match incidence rates of all. No pooled effect size or formal statistical trend test is reported, only descriptive incidence rates compared across studies and time periods.

Question 2

What was the study design?

Accepted Answer

This is a narrative synthesis of previously published injury surveillance studies (cohort observational data), not a formal systematic review or meta-analysis; it sits at the lower end of the evidence hierarchy for pooled estimates, built on individually reasonable prospective surveillance cohorts from elite leagues in six countries plus UEFA competitions.

Question 3

How trustworthy is the methodology?

Accepted Answer

The 10 source studies were identified via existing systematic reviews plus 'targeted searches', a step that is not a reproducible systematic search strategy and opens the door to selection bias in which studies get included. There is no stated risk of bias or quality grading (no GRADE, no ROBINS style tool) and no meta analytic pooling, so the 'stable trend' claim is read off a table rather than tested statistically. The underlying studies also differ in exposure definitions (match only vs match plus training, hours based rates vs per team per season counts) and in professionalisation level of the leagues studied, which limits direct comparability. A clinician wanting to verify the central claim would need to pull the incidence per team per season figures from each cited study's table and check the exposure denominators line up.

Question 4

What is the overall appraisal?

Accepted Answer

The core observation, that incidence rate per team per season has not risen and stays under 1 in nearly all datasets, looks statistically unremarkable rather than alarming, so the 'epidemic' framing is not supported by rate data as presented. But a flat or falling rate does not rule out a rising absolute burden: if the number of professional teams, matches and media scrutiny has grown sharply, total ACL injuries and their visibility can increase even while the per team rate stays flat, and the paper does not fully reconcile that distinction. The design supports a descriptive, corrective claim about incidence rates; it does not support a strong causal or comparative claim about why perception and reality diverge.

Question 5

What is the main limitation?

Accepted Answer

There is no statistical test of trend over time and no accounting for how much professional women's football has expanded (more teams, more matches, more surveillance coverage), so it remains unclear whether absolute ACL case counts, and therefore real world clinical and system burden, have risen even if the per team rate has not. The ten studies were also identified through existing systematic reviews plus 'targeted searches' rather than a de novo systematic search with risk of bias appraisal, and the paper's explicit aim is to rebut a specific media narrative, so which surveillance datasets got included carries some confirmation bias risk. Surveillance definitions also differ across the six countries and 25 years sampled (exposure hours vs team season, clinician confirmed diagnosis vs self report, competition tier), so the apparent consistency in rates partly reflects comparing similar but not identical metrics.

Question 6

What should clinicians do on Monday?

Accepted Answer

This does not change on field assessment, rehab, or return to sport decisions for an individual athlete with an ACL injury; its practical use is for clinicians and staff fielding questions from athletes, media or administrators, where it supports framing ACL risk in women's football as persistently elevated relative to men but not acutely worsening, rather than repeating 'epidemic' language.

Question 7

How do I apply this in practice?

Accepted Answer

This doesn't touch individual ACL assessment, rehab progression or RTS criteria, those stay governed by strength symmetry, hop testing and psychological readiness regardless of league level epidemiology. Its real value is in the conversation with players, parents, press and administrators: physios and S&C coaches can now say accurately that incidence per team season has stayed flat and low for 25 years, while still being clear that women's ACL risk remains several fold higher than men's, so existing primary prevention work (neuromuscular warm ups, Nordic/hamstring loading, landing mechanics coaching) should continue unchanged, not be scaled back because 'the epidemic isn't real.' On the S&C floor, if a club or league tries to use this paper to justify cutting ACL risk reduction budgets or screening, push back: a flat rate at a persistently elevated level, inside an expanding league system with more teams and matches, can still mean a rising absolute caseload and rehab workload for your staff. Treat this as league level discourse correction, not as evidence that your specific club's surveillance, pitch surface, fixture congestion or squad behaves the same as the sampled top leagues.

'ACL epidemic in women's football': the epidemiological evidence does not support the narrative

The paper

What they found

Study design

Methodology

The appraisal

The gap

Landmark context

What to do Monday

In practice

The five papers that matter — every week, free.

Related appraisals